TP53 and sarcoma: Twenty-four patients enrolled in the phase I trial of ixazomib and vorinostat had colorectal carcinoma (n = 20) or sarcoma (n = 4) with TP53 hotspot mutations, and 6 patients enrolled in the phase I trial of pazopanib and vorinostat had colorectal carcinoma (n = 3) or sarcoma (n = 3) with TP53 hotspot mutations.